Meagan Deming

Assistant Professor

University of Maryland Center for Vaccine Development

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Meagan Deming is an Assistant Professor at the University of Maryland Center for Vaccine Development in the United States. Her research focuses on vaccine efficacy and immunogenicity, particularly pertaining to SARS-CoV-2 and COVID-19 variants. Recent publications include studies on antibody responses to bivalent mRNA vaccines and the role of self-assessed symptom severity in determining COVID-19 outcomes.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Rebecca Brady

Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

View details

Vaidehi Agrawal

University of Maryland

UNITED STATES

View details

Christopher Chiu

Professor of Infectious Diseases

Imperial College London

UNITED KINGDOM

View details

DeAnna Friedman-Klabanoff

Assistant Professor

University of Maryland School of Medicine

UNITED STATES

View details

John Williams

Assistant Professor

University of New Mexico

UNITED STATES

View details

Helen C. Stankiewicz Karita

University of Washington

UNITED STATES

View details

Christina Rostad

Assistant Professor

Emory University School of Medicine

UNITED STATES

View details

Simon Kolstoe

Academic, Reader, Reader in Bioethics

University of Portsmouth

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Meagan Deming

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies – A stakeholder meeting report

Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.

Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA–Positive Samples

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

Homologous and Heterologous Covid-19 Booster Vaccinations

Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study.

Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission

Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity

A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model

A ‘mix and match’ approach to SARS-CoV-2 vaccination

Decline in COPD Admissions During the COVID-19 Pandemic Associated with Lower Burden of Community Respiratory Viral Infections.

Collaborators (8)

Rebecca Brady

Vaidehi Agrawal

Christopher Chiu

DeAnna Friedman-Klabanoff

John Williams

Helen C. Stankiewicz Karita

Christina Rostad

Simon Kolstoe

Make your next move.